Trevi Therapeutics (TRVI) Cash from Investing Activities (2018 - 2026)

Trevi Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $17.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 270.49% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at -$67.2 million (down 187.29% YoY), while the FY2025 annual figure was -$94.1 million, down 337.14% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $17.0 million, up from -$30.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $19.6 million in Q2 2023, with the low at -$50.9 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is -$2.6 million (2025), against an average of -$6.2 million.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities jumped 470.76% in 2023, then slumped 764.38% in 2025.
• Trevi Therapeutics' Cash from Investing Activities stood at -$48.3 million in 2022, then jumped by 126.59% to $12.8 million in 2023, then plunged by 285.85% to -$23.9 million in 2024, then fell by 28.22% to -$30.6 million in 2025, then soared by 155.43% to $17.0 million in 2026.
• Business Quant data shows TRVI's Cash from Investing Activities at $17.0 million in Q1 2026, -$30.6 million in Q4 2025, and -$50.9 million in Q3 2025.